- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
James Galeota, Merck
S
James Galeota
SVP, General Manager, Diabetes and Obesity, Merck
BIGGEST ACCOMPLISHMENT: Establishing Merck's diabetes franchise
ADMIRES: Those that can help others live up to their potential
On stopping the silos:
Commercialization is not about discreet disciplines. At Merck, I have been able to see into different parts of the company and see the value that can be created when all the divisions are synchronized—when you have teams that are aligned around objectives, sharing the same measures of success, holding each other accountable, and working together to solve complex problems.
James Galeota
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
